Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis

Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume (45.5% improved and 34.1% preserved) at Month 48 of the DAYBREAK open-label extension trial Zeposia was well tolerated, with more than 80% of people staying … [Read more…]

New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)

Analysis of ongoing DAYBREAK open-label extension trial of Zeposia showed that seroconversion occurred in 100% of those treated with mRNA vaccines and in a majority of those treated with non-mRNA vaccines New analyses to be featured in late-breaking research session at the 8th European Academy of Neurology Congress in Vienna, Austria Data are among five … [Read more…]

Lutetium-177 (Lu-177) Market and Pipeline Analysis Research Report 2022 – Global Forecast to 2028 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering. Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast to 2028″ gives comprehensive insights on the various Lu-177 based drugs being developed for the treatment of prostate cancer, NETs, Lung cancer, solid tumors and other … [Read more…]

New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

— Data being presented at the European Academy of Neurology Congress demonstrates consistent reductions in NMOSD attacks and disability scores across populations — DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced new findings from a post hoc analysis of the N-MOmentum Phase 3 pivotal trial of UPLIZNA supporting the medicine’s efficacy in Europeans living with … [Read more…]

US Specialty Drug Distribution Market Research Report 2022-2027: Market Set to Grow to $747.03 Million By 2027 with Compound Annual Growth at 13.99% – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Specialty Drug Distribution Market Research Report by Indication (AIDS, Hemophilia, and Multiple Sclerosis), Type, Distribution Type, Distribution Channel, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The United States Specialty Drug Distribution Market size was estimated at USD 340.41 million in 2021 … [Read more…]

Global Body Contouring Market (2022 to 2027) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Body Contouring Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global body contouring market reached a value of $7.3 Billion in 2021. Looking forward, the publisher expects the market to reach $11.1 Billion by 2027, exhibiting a CAGR of 6.9% during 2022-2027. … [Read more…]

Urethral Cancer Drugs Pipeline Guide 2022: Key Players, Developments and Established Therapeutics – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Urethral Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. Scope The pipeline guide provides a snapshot of the global therapeutic landscape of Urethral Cancer The pipeline guide reviews pipeline therapeutics for Urethral Cancer by companies and universities/research institutes based on … [Read more…]

Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease

SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”) in patients with macular atrophy secondary to Stargardt disease. The study was a multi-center, randomized, double-masked, and placebo-controlled phase 3 … [Read more…]

Geographic Atrophy Drugs in Development Pipeline Guide 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Geographic Atrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under development for Geographic Atrophy, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and … [Read more…]

Worldwide Systemic Sclerosis-associated Interstitial Lung Disease Industry to 2032 – Insight, Epidemiology and Market Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering. This report delivers an in-depth understanding of the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), historical and forecasted epidemiology as well as the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market trends in the … [Read more…]